Research

Dr. Bart Jacobs, Vice Chairman of GMAB, and co-authors, get “Editor’s Choice,” Brain Journal

An article published in Brain Journal, September 25, 2018, regarding research findings of the International Guillain Barre Outcome Survey (IGOS), partially supported by GBS|CIDP Foundation International, received the “Editor’s Choice.” Findings of IGOS are significant to the GBS community as noted in the abstract summary of article

Read More about Dr. Bart Jacobs, Vice Chairman of GMAB, and co-authors, get “Editor’s Choice,” Brain Journal
CIDP Disease Burden — Results of a US Nationwide Patient Survey

CIDP Disease Burden — Results of a US Nationwide Patient Survey

In 2017, a nationwide survey of US CIDP patients was conducted to assess the impact of disease-related disability and treatment on lifestyle and work activities. Approximately 3250 individuals aged ≥18 years, recruited by the GBS|CIDP Foundation and self-reported to have CIDP, were invited to complete an online survey; of these, 475 completed the survey and…

Read More about CIDP Disease Burden — Results of a US Nationwide Patient Survey

Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP

David Saperstein, MD Co-Director GBS/CIDP Center of Excellence Phoenix Neurological Associates Phoenix, AZ Intravenous immunoglobulin (IVIg) is one of the main therapies used to treat CIDP. This therapy can be very effective but there are drawbacks. Some people experience headaches related to the intravenous infusions. Some people have difficulty with IV access. Also, the need…

Read More about Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP